Compare Moderna, Inc. (MRNA) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prologis Inc — how do they compare? Moderna, Inc. trades at $213.99 (market cap $78.65B), while Prologis Inc trades at $128.73 (market cap $122.87B). The key difference: Prologis Inc is the larger of the two by market cap, and Prologis Inc pays a 3.31% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Prologis Inc for 102 Days on average.
| MRNA | PLD | |
|---|---|---|
Market Cap | $78.65B | $122.87B |
Volume | 37,373,437 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $203.46 | $149.96 |
52-Week Low | $22.36 | $111.23 |
Typical Hold Time | 59 Days | 102 Days |
Enterprise Value | $74.80B | $157.61B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Prologis (PLD) trades at $127.3, down 1.07% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by robust leasing activity and data center expansion, while profitability remains high with a net income margin of 45.79%. Analyst consensus is bullish with a $155.15 price target, though technical indicators show near-term pressure.
The outlook for PLD is positive due to its leading position in industrial real estate, driven by e-commerce and data center demand. Risks include rising debt levels and market volatility. Institutional buying and strong analyst support suggest long-term upside, but investors should monitor debt management and macroeconomic trends affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
